---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-071093"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2023-12-18T23:59:59+00:00"
generated_at: "2026-06-07T11:13:10.326883+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics amends bylaws to align with universal proxy rules and update stockholder meeting procedures

## Summary
- Board approved amended bylaws effective Dec 14, 2023, addressing SEC universal proxy Rule 14a-19.
- New rules require additional disclosures from stockholders nominating directors or proposing business.
- Stockholders soliciting proxies must use a non-white proxy card; obsolete provisions deleted.
- Changes are procedural and governance-related; no financial impact disclosed.

## SEC filing metadata
- accession: 0000950170-23-071093
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2023-12-18T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/0000950170-23-071093-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/lyra-20231214.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-071093
- JSON: https://secwatch.observer/filing/0000950170-23-071093.json
- Plain text: https://secwatch.observer/filing/0000950170-23-071093.txt

## Key facts
- Governance Changes
  Lyra Therapeutics, Inc.: Amended and restated bylaws to address universal proxy rules, streamline stockholder nomination and proposal procedures, require a non-white proxy card for soliciting stockholders, and delete obsolete provisions with technical changes (effective 2023-12-14).
  - Change: bylaw amendment
  - Effective: 2023-12-14
  source text: On December 14, 2023, the Board of Directors (the “ Board ”) of Lyra Therapeutics, Inc., a Delaware corporation (the “ Company ”) approved and adopted amendments to the Company’s amended and restated bylaws (as amended, the “ Amended and Restated Bylaws ”), which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1327273/000095017023071093/0000950170-23-071093-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.